MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1352458515623862

Медицинская библиотека · Multiple sclerosis (Houndmills, Basingstoke, England) · 2016

MS arising during Tocilizumab therapy for rheumatoid arthritis.

Beauchemin Philippe, Carruthers Robert

Клинический случайСтатьяПеревод в очереди

Аннотация

BACKGROUND

Interleukin-6 (IL6) blockage is a treatment strategy used in many inflammatory conditions. Trials in Neuromyelitis Optica Spectrum Disorder (NMOSD) are ongoing. Secondary auto-immunity affecting the central nervous system (CNS) is well described with some biologic agents, mainly tumor necrosis factor (TNF)-alpha inhibitors. These treatments can also aggravate patients with known multiple sclerosis (MS).

OBJECTIVES

To describe a case of a patient who developed MS using another biologic, IL6 receptor antibody Tocilizumab.

RESULTS

A 48-year-old woman developed MS while on treatment with Tocilizumab for Rheumatoid Arthritis (RA). This is the first published report of this association. It has obvious implications for NMOSD patients receiving anti-IL6 therapy. Development of new white matter lesions suggestive of MS in a patient treated with anti-IL6 therapy might represent an important complication of therapy.

CONCLUSION

This case illustrates that Tocilizumab might cause secondary auto-immunity in CNS. It is important to be aware of this potential complication as anti-IL6 therapy might become an option for the treatment NMOSD.

Для цитирования: Beauchemin Philippe, Carruthers Robert. MS arising during Tocilizumab therapy for rheumatoid arthritis.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016. DOI: 10.1177/1352458515623862.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.